Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients (Q34084546)

30 July 2017

title

Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients (English)

1 reference

30 July 2017

0 references

1 reference

2

Matteo Monami

1 reference

30 July 2017

1

Edoardo Mannucci

1 reference

30 July 2017

Daniela Balzi

3

1 reference

30 July 2017

Barbara Cresci

4

1 reference

30 July 2017

Laura Pala

5

1 reference

30 July 2017

Cecilia Melani

6

1 reference

30 July 2017

Caterina Lamanna

7

1 reference

30 July 2017

Ilaria Bracali

8

1 reference

30 July 2017

Michela Bigiarini

9

1 reference

30 July 2017

Alessandro Barchielli

10

1 reference

30 July 2017

Niccolo Marchionni

11

1 reference

30 July 2017

Carlo Maria Rotella

12

1 reference

30 July 2017

language of work or name

English

0 references

publication date

14 June 2010

1 reference

30 July 2017

1 reference

30 July 2017

volume

33

1 reference

30 July 2017

issue

9

1 reference

30 July 2017

page(s)

1997-2003

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

30 July 2017

copyright license

start time

28 August 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Insulin glargine and malignancy: an unwarranted alarm

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Sulphonylureas and cancer: a case-control study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Metformin and reduced risk of cancer in diabetic patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Long-acting insulin analogs.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Validation of a combined comorbidity index

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2928350

1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization

28 October 2018

1 reference

12 December 2020

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

12 December 2020

Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis

1 reference

12 December 2020

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

1 reference

12 December 2020

No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis

1 reference

12 December 2020

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

1 reference

12 December 2020

Identifiers

DOI

10.2337/DC10-0476

1 reference

30 July 2017

0 references

1 reference

30 July 2017

1 reference